Game Changers: How Lorlatinib Shifts the Landscape
AI Summary
Lorlatinib is revolutionizing the treatment of ALK-positive non-small cell lung cancer (NSCLC), delivering remarkable 5-year progression-free survival rates that surpass previous therapies. Dr. Mark Kris highlights its potential while also addressing the unique toxicities associated with it, which is crucial for clinicians to effectively manage patient care. This advancement marks a significant shift in how oncologists approach this specific cancer type, offering hope for better long-term outcomes for patients.
Original Source
Read the full article at Medscape →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.